Results 81 to 90 of about 118,212 (266)
Regulatory agencies request the assessment of the potential of new drugs to cause transporter‐mediated drug‐drug interactions (DDI). This assessment can be improved by integrating endogenous biomarkers during drug development. Regarding the renal excretion of drugs such as metformin, the organic cation transporter (OCT) 2 and multidrug and toxin ...
Jana Picurová +5 more
wiley +1 more source
Metformin, a widely prescribed anti-diabetic drug, shows anticancer activity in various cancer types. Few studies documented that there was a decreased level of LDL and total cholesterol in blood serum of metformin users. Based on these views, this study
Ankit Sharma +8 more
doaj +1 more source
A bifunctional molecular bridge using 4‐guanidinobutanoic acid (GCC) is constructed to comprehensively tailor the buried interface of PSCs. By passivating oxygen vacancies, optimizing energy‐level matching, and regulating perovskite crystallization, this strategy simultaneously boosts the power conversion efficiency to 25.37% (20.01% for 13.4 cm2) and ...
Ying Liang +12 more
wiley +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
BackgroundMetformin is commonly used as adjunctive therapy in adults with type 1 diabetes (T1DM), although evidence regarding its long-term metabolic effects remains inconsistent.
Małgorzata Bekier +5 more
doaj +1 more source
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source
Pre-Treatment with Metformin in Comparison with Post-Treatment Reduces Cerebral Ischemia Reperfusion Induced Injuries in Rats [PDF]
Objective: To explore the effects of pre versus post ischemic treatment with metformin after global cerebral ischemia in rats.Methods: Male Wister rats underwent forebrain ischemia by bilateral common carotid artery occlusion for 17 min.
Mojtaba Karimipour +3 more
doaj
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
The Effect of Metformin on Pregnancy Outcome Among Filipino Women with Polycystic Ovary Syndrome
Objective.To determine the effect of metformin on maternal and neonatal outcome among pregnant Filipino women with polycystic ovary syndrome (PCOS). Methodology.This is a retrospective cohort study of PCOS women who were on metformin treatment prior
May Uyking-Naranjo +3 more
doaj
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source

